![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 09, 2019 1:13:15 PM
To all Investors,
* Please be advised we will be changing our company name from Lexington Bioscience to HEART SENTRY as of February 1st 2019. Our stock symbols LNB and LXGTF will remain the same until a change is approved for NASDQ listing.
* There should be no changes to your investment at this time although we can not guarantee that in the near future.
*We have held intensive discussions with various Universities over the last few months and have chosen the University of Florida to conduct the continuation of testing due to the unlimited Senior Citizen population.
*Testing is planned to commence March 1st 2019 with a proposed conclusion by August 2019.
Thereafter submitting our results to the FDA for approval and a speedy initial distribution to major US Healthcare Facilities shortly afterwards.
Thank You for your continued support.
Eric Willis
President Lexington Bioscience (Heart Sentry)
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM